BackInfinity Pharmaceuticals Overview

Infinity Pharmaceuticals Other Current Liabilities

Infinity Pharmaceuticals's other current liabilities is $1.7M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$1.65M
86.80% YoYΔ $-10.87M vs prior year quarter

Peer trimmed avg / median

Loading

Infinity Pharmaceuticals Other Current Liabilities History

Loading

Infinity Pharmaceuticals vs. peers: Other Current Liabilities Comparison

Loading

Infinity Pharmaceuticals Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Infinity Pharmaceuticals (INFI) FAQ

As of the most recent data (June 2023), INFI shows a other current liabilities of $1.7M. That compares with $13M in the prior-year period — down 86.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, INFI's other current liabilities is now $1.7M (was $13M) — a 86.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Infinity Pharmaceuticals is outperforming or lagging.

Tracking INFI's other current liabilities over time shows whether Infinity Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $1.7M That compares with $13M in the prior-year period — down 86.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Infinity Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $1.7M) with ownership activity and broader fundamentals.

Infinity Pharmaceuticals's other current liabilities is $1.7M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.